EUVIMEDEUVIMED entdecken
Multizentrische Studie

Utility and optimal management of planned drug holidays during lenvatinib treatment in patients with unresectable differentiated thyroid cancer: a real-world multi-center study

Takuya Mikoshiba iD, Mariko Sekimizu, Takeyuki Kono, Ryoto Nagai, Taiji Kawasaki, Yoichiro Sato, Fumihiro Ito, Nana Nakahara, Seiji Shigetomi, Hiroyuki Ozawa

Endocrine · 2024

DOI: 10.1007/s12020-024-03744-0 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Endocrine, 2024. Verfasst von Takuya Mikoshiba und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Otolaryngology, Head and Neck Surgery, Keio University School of Medicine, Tokyo, Japan. takmikoshiba@yahoo.co.jp. Hauptthemen laut MEDLINE: Thyroid Neoplasms, Quinolines, Phenylurea Compounds, Antineoplastic Agents. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 19 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: Lenvatinib achieves favorable therapeutic outcomes for patients with radioactive iodine therapy refractory differentiated thyroid cancer (DTC); however, its use is associated with a high incidence of adverse events. To avoid severe adverse events, planned drug holidays (PDH) have been proposed. This study aimed to evaluate treatment effects, identify prognostic factors, and investigate the usefulness of PDH in patients with unresectable DTC who received lenvatinib across the multi-institutions. METHODS: Fifty-one patients with unresectable DTC treated with lenvatinib were evaluated retrospectively. Overall survival (OS) and progression-free survival (PFS) were calculated, and prognostic factors were assessed. OS, PFS, and time to treatment failure (TTF) were compared between patients with and without PDH. Lenvatinib administration schedule was evaluated in PDH. RESULTS: The 3-year OS and PFS rate were 53.5% and 42.1%, respectively. Multivariate analysis revealed that presence of maximum size of lung metastasis ≥10 mm was independent prognostic factor for poorer OS and PFS, and histology other than papillary thyroid carcinoma was the independent prognostic factor for poorer PFS. Twenty-five patients (49%) treated with PDH. There were significant differences in OS, PFS, and TTF between patients with and without PDH. Various schedules were used in PDH. Eight (32%) patients required switch to the different administration schedule. CONCLUSION: Our results suggest that PDHs may extend OS, PFS, and TTF. In patients with PDH, various schedules used for lenvatinib administration highlight the difficulty in determining a uniform administration schedule. Therefore, it is crucial to consider the optimal lenvatinib administration schedule on a case-by-case basis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Thyroid NeoplasmsQuinolinesPhenylurea CompoundsAntineoplastic AgentsHumansMaleFemaleMiddle AgedRetrospective StudiesAdultAgedTreatment OutcomePrognosisDrug Administration Schedule

Stichwörter der Autor:innen

Adverse eventsLenvatinibPlanned drug holidaysPrognosisThyroid cancer

Substanzen

lenvatinibQuinolinesPhenylurea CompoundsAntineoplastic Agents

Autor:innen und Institutionen

  • Department of Otolaryngology, Head and Neck Surgery, Keio University School of Medicine, Tokyo, Japan. takmikoshiba@yahoo.co.jp.
  • Department of Otolaryngology, Head and Neck Surgery, Keio University School of Medicine, Tokyo, Japan.
  • Department of Otolaryngology, Head and Neck Surgery, Japanese Red Cross Shizuoka Hospital, Shizuoka, Japan.
  • Department of Otolaryngology, Saiseikai Utsunomiya Hospital, Tochigi, Japan.
  • Department of Otolaryngology, National Tokyo Medical Center, Tokyo, Japan.
  • Department of Otolaryngology, Saitama City Hospital, Saitama, Japan.

ORCID-Profile: Takuya Mikoshiba

Zitieren

APA

Mikoshiba, T., Sekimizu, M., Kono, T., Nagai, R., Kawasaki, T., Sato, Y., Ito, F., Nakahara, N., Shigetomi, S., & Ozawa, H. (2024). Utility and optimal management of planned drug holidays during lenvatinib treatment in patients with unresectable differentiated thyroid cancer: a real-world multi-center study. Endocrine. https://doi.org/10.1007/s12020-024-03744-0

Vancouver

Mikoshiba T, Sekimizu M, Kono T, Nagai R, Kawasaki T, Sato Y, et al. Utility and optimal management of planned drug holidays during lenvatinib treatment in patients with unresectable differentiated thyroid cancer: a real-world multi-center study. Endocrine. 2024. doi:10.1007/s12020-024-03744-0

BibTeX
@article{Mikoshiba2024,
  author = {Mikoshiba, Takuya and Sekimizu, Mariko and Kono, Takeyuki and Nagai, Ryoto and Kawasaki, Taiji and Sato, Yoichiro and Ito, Fumihiro and Nakahara, Nana and Shigetomi, Seiji and Ozawa, Hiroyuki},
  title = {Utility and optimal management of planned drug holidays during lenvatinib treatment in patients with unresectable differentiated thyroid cancer: a real-world multi-center study},
  journal = {Endocrine},
  year = {2024},
  doi = {10.1007/s12020-024-03744-0}
}
Kostenlos starten →